SBFM - Chinese Lockdown Effects Ripple Marketwide; A Solution Urgently Needed
(NewsDirect)
Read the latestreport on Sunshine Biopharma here .
Protests have mounted in intensity acrossChina in the past weeks, as more and more citizens become frustratedwith the country’s radical “Zero-Covid” policies. This was partof the cause for the markets havinga rocky opening last week, with Tesla, Inc. (NASDAQ:TSLA) and Apple, Inc. (NASDAQ: AAPL) stock falling and awidespread drop in the oil sector in response to the continuinginstability.
Thisuncertainty is a reminder that, even as some describe living with thevirus as a ‘new normal,’ complacency toward Covid carries risks.Clearly, there is a need for more effective solutions.
Sunshine Biopharma, Inc. (NASDAQ:SBFM) is a Canada-based pharmaceutical company combating COVID-19through the development of SBFM-PL4, an antiviral treatment. Itbelieves this drug, which it anticipates could be taken in tablet formfrom home, could be the kill shot for COVID and could help finally putan end to the pandemic.
Partnering With The University ofArizona University For Covid Research
A fully integrated pharmaceutical company,Sunshine Biopharma specializes in the research and development(R&D) of oncological and antiviral treatments and has multipleongoing development projects, including SBFM-PL4. The strongteam at Sunshine recently started a collaboration with the University of Arizona. Led by Dr. GregoryThatcher, the collaboration will continue research into SBFM-PL4, andinvolve testing PLpro inhibitors to see how the drug reacts with theimmune system.
While companies like Pfizer (NYSE: PFE), Eli Lillyand Co. (NYSE: LLY), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) have developed treatments for COVID, concernsaround these drugs range from their limited efficacy toquestions around their safety and drug resistance.
Meanwhile, Sunshine’sdrug targets nsp3 protease, the enzyme which suppresses thepatient’s immune system and allows the Covid virions to effectmaximal damage. As an nsp3 protease inhibitor, SBFM-PL4 doesn’tmerely weaken the virus, like other treatments, but also supportsoverall health by allowing the patient’s immune system to fightback. The company is confident that, in a Covid-19 vaccine market worth$13.6 billion , its drug candidate could provide a welcomesolution.
“Itis urgent that effective treatments and more specific vaccines bedeveloped at an accelerated pace,” said Dr. Steve Slilaty, CEO ofSunshine Biopharma. “We are delighted to be working with Dr. GregoryThatcher, who is aiming to find a wide array of inhibitors for PLpro(also called nsp3), as this virus-encoded protease is responsible forthe suppression of the human immune system.”
Along with thisimportant collaboration, Sunshine Biopharma can reflect proudly on ayear that saw the company report growth in its financial position and a recentacquisition that may help the company enter the genericprescription drug market and become profitable. It is also developing a drug – Adva-27a – which it believes will be successful intreating various forms of multidrug-resistant cancer. In addition, thecompany is developing a vaccine-like mRNA treatment for cancer.
Want to learn more about Sunshine Biopharma?Visit its website .
In addition to working with the University of Arizona on thedevelopment of a treatment for COVID-19, Sunshine Biopharma is engagedin the development Adva-27a, a unique anticancer compound. Testsconducted to date have demonstrated the effectiveness of Adva-27a atdestroying Multidrug Resistant Cancer Cells, including PancreaticCancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, andUterine Sarcoma cells. Clinical trials for Pancreatic Cancerindication are planned to be conducted at McGill University’s JewishGeneral Hospital in Montreal, Canada. Sunshine Biopharma is alsoengaged in the development of a novel anticancer mRNA called K1.1. Thedata collected to date have shown that K1.1 mRNA is capable ofdestroying cancer cells in vitro including multidrug resistant breastcancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), andpancreatic cancer cells (SUIT-2). Studies using non-transformed(normal) human cells (HMEC) have shown that K1.1 mRNA had little or nocytotoxic effects. K1.1 mRNA is readily adaptable for delivery intopatients using the proven mRNA vaccine technology.
Thispost contains sponsored advertising content. This content is forinformational purposes only and is not intended to be investingadvice.
Contact Details
Christine Petraglia -TraDigital IR
+1 917-633-8980
investors@sunshinebiopharma.com
CompanyWebsite
https://sunshinebiopharma.com/
Copyright (c) 2022 TheNewswire - All rights reserved.